View Financial HealthiFabric 配当と自社株買い配当金 基準チェック /06iFabric配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • 1h+ 1 more updateiFabric Corp. to Report Q1, 2026 Results on May 14, 2026iFabric Corp. announced that they will report Q1, 2026 results on May 14, 2026お知らせ • Apr 28iFabric Corp., Annual General Meeting, Jun 29, 2026iFabric Corp., Annual General Meeting, Jun 29, 2026. Location: ontario, markham Canadaお知らせ • Aug 22iFabric Corp. Announces Publication of Groundbreaking Clinical Trial Providing the Infection Convenience Capability of PROTX2 and ecoPEL Treated ScrubsiFabric Corp. announced that the results of its clinical trial, "Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs, has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience. The study-conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. "IFTNA" at MemorialCare Saddleback Medical Center in Southern California under the leadership of Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN;leen M. Young, MSN, RN, NPD-BC;andi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD- BC-marks the first successful antimicrobial textile trial of its kind to demonstrate statistically significant reductions in bacterial loads on scrubs worn in a real-world healthcare setting. This trial conclusively showed that scrubs treated with PROTX2 and PROTX2 combined with ecoPEL Fluorine-Free Durable Water Repellent (DWR) technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs -proof that these proprietary technologies can deliver infection control performance unmatched in the industry. As a nonprofit, all revenue is reinvested into patient care, technology, and facility improvements, supported by the Saddleback Medical Center Foundation, which has fostered community partnership and philanthropy since founding. With over 500 affiliated clinicians, the company provide a full spectrum of inpatient, surgical, and outpatient services-including urgent care, advanced imaging, joint replacement, infusion therapy, stroke care, and rehabilitation-ensuring accessible, high-quality care for every stage of life. At Saddleback Medical Center, compassionate care, medical excellence, and community partnership remain at the heart of its mission.お知らせ • May 08iFabric Corp. to Report Q1, 2025 Results on May 15, 2025iFabric Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025お知らせ • Apr 23iFabric Corp., Annual General Meeting, Jun 24, 2025iFabric Corp., Annual General Meeting, Jun 24, 2025. Location: ontario, markham Canadaお知らせ • Mar 14iFabric Corp. Provides Sales Guidance for the Full Year 2024iFabric Corp. provided Sales guidance for the full year 2024. For the year, the company expects sales to the range of $28 million to $32 million.お知らせ • Nov 10iFabric Corp. Announces Expansion MoveiFabric Corp. announced that it has executed a lease agreement for the rental of approximately 5,000 square feet of office space in Markham, Ontario, at a commercial office building near its current head office and warehouse location. The new offices will house the Canadian management and administrative personnel of the Company. After the move, the current Company owned building located at 525 Denison Street, Markham, Ontario, which currently comprises a mix of warehouse and office space, will be fully repurposed as warehouse space. The new office lease agreement is for a period of 5 years commencing on April 1, 2024, and expiring March 31, 2029, with the option to renew for a further period of 5 years. iFabric's personnel will be occupying temporary space at the new location, until such time as the required leasehold improvements to its new premises have been completed.お知らせ • Jul 06iFabric Corp. Announces the Successful Results of the Clinical Trial Utilizing Protx2 Treated ScrubsiFabric Corp. provided an update on the outcome of the clinical trial conducted by its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). The objective of the trial was to empirically demonstrate the reduction in bacterial loads on PROTX2 treated scrubs vs standard off the shelf untreated scrubs, when used in a healthcare environment. Three sets of scrubs were produced for the trial; one set treated with ProTX2 only, a second set with Protx2 and proprietary DWR (durable water repellant) technology and, a third set with no technologies applied (the control). The summary of the trial findings is that both the PROTX2 and the PROTX2 with DWR treated scrubs demonstrated statistically significant reductions in bacterial loads on the surfaces of scrubs, as compared to untreated scrubs. The term statistically significant is used to describe a result that is highly unlikely to occur by chance alone in a natural environment. The results achieved in the study demonstrate that proprietary technologies were uniquely responsible for the reduction in bacterial loads witnessed throughout the trial. The next and final phase of this trial is to submit the study to a recognized medical journal for peer review.決済の安定と成長配当データの取得安定した配当: IFAB.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: IFAB.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場iFabric 配当利回り対市場IFAB.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (IFAB.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Luxury)2.6%アナリスト予想 (IFAB.F) (最長3年)n/a注目すべき配当: IFAB.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: IFAB.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: IFAB.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: IFAB.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/13 14:14終値2026/05/13 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋iFabric Corp. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Nicholas CortellucciAtrium ResearchDoug CooperBeacon Securities Limited
お知らせ • 1h+ 1 more updateiFabric Corp. to Report Q1, 2026 Results on May 14, 2026iFabric Corp. announced that they will report Q1, 2026 results on May 14, 2026
お知らせ • Apr 28iFabric Corp., Annual General Meeting, Jun 29, 2026iFabric Corp., Annual General Meeting, Jun 29, 2026. Location: ontario, markham Canada
お知らせ • Aug 22iFabric Corp. Announces Publication of Groundbreaking Clinical Trial Providing the Infection Convenience Capability of PROTX2 and ecoPEL Treated ScrubsiFabric Corp. announced that the results of its clinical trial, "Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs, has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience. The study-conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. "IFTNA" at MemorialCare Saddleback Medical Center in Southern California under the leadership of Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN;leen M. Young, MSN, RN, NPD-BC;andi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD- BC-marks the first successful antimicrobial textile trial of its kind to demonstrate statistically significant reductions in bacterial loads on scrubs worn in a real-world healthcare setting. This trial conclusively showed that scrubs treated with PROTX2 and PROTX2 combined with ecoPEL Fluorine-Free Durable Water Repellent (DWR) technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs -proof that these proprietary technologies can deliver infection control performance unmatched in the industry. As a nonprofit, all revenue is reinvested into patient care, technology, and facility improvements, supported by the Saddleback Medical Center Foundation, which has fostered community partnership and philanthropy since founding. With over 500 affiliated clinicians, the company provide a full spectrum of inpatient, surgical, and outpatient services-including urgent care, advanced imaging, joint replacement, infusion therapy, stroke care, and rehabilitation-ensuring accessible, high-quality care for every stage of life. At Saddleback Medical Center, compassionate care, medical excellence, and community partnership remain at the heart of its mission.
お知らせ • May 08iFabric Corp. to Report Q1, 2025 Results on May 15, 2025iFabric Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025
お知らせ • Apr 23iFabric Corp., Annual General Meeting, Jun 24, 2025iFabric Corp., Annual General Meeting, Jun 24, 2025. Location: ontario, markham Canada
お知らせ • Mar 14iFabric Corp. Provides Sales Guidance for the Full Year 2024iFabric Corp. provided Sales guidance for the full year 2024. For the year, the company expects sales to the range of $28 million to $32 million.
お知らせ • Nov 10iFabric Corp. Announces Expansion MoveiFabric Corp. announced that it has executed a lease agreement for the rental of approximately 5,000 square feet of office space in Markham, Ontario, at a commercial office building near its current head office and warehouse location. The new offices will house the Canadian management and administrative personnel of the Company. After the move, the current Company owned building located at 525 Denison Street, Markham, Ontario, which currently comprises a mix of warehouse and office space, will be fully repurposed as warehouse space. The new office lease agreement is for a period of 5 years commencing on April 1, 2024, and expiring March 31, 2029, with the option to renew for a further period of 5 years. iFabric's personnel will be occupying temporary space at the new location, until such time as the required leasehold improvements to its new premises have been completed.
お知らせ • Jul 06iFabric Corp. Announces the Successful Results of the Clinical Trial Utilizing Protx2 Treated ScrubsiFabric Corp. provided an update on the outcome of the clinical trial conducted by its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). The objective of the trial was to empirically demonstrate the reduction in bacterial loads on PROTX2 treated scrubs vs standard off the shelf untreated scrubs, when used in a healthcare environment. Three sets of scrubs were produced for the trial; one set treated with ProTX2 only, a second set with Protx2 and proprietary DWR (durable water repellant) technology and, a third set with no technologies applied (the control). The summary of the trial findings is that both the PROTX2 and the PROTX2 with DWR treated scrubs demonstrated statistically significant reductions in bacterial loads on the surfaces of scrubs, as compared to untreated scrubs. The term statistically significant is used to describe a result that is highly unlikely to occur by chance alone in a natural environment. The results achieved in the study demonstrate that proprietary technologies were uniquely responsible for the reduction in bacterial loads witnessed throughout the trial. The next and final phase of this trial is to submit the study to a recognized medical journal for peer review.